SOURCE: SkyePharma PLC

October 08, 2007 02:05 ET

SkyePharma PLC announces Change of Marketing Partner

London, UK--(Marketwire - October 8, 2007) -

For Immediate Release                                     8 October 2007


                     Solaraze -Change of Marketing Partner
LONDON, UK - 8 October 2007 -- SkyePharma PLC (LSE: SKP) announces that the distribution and marketing rights for Solaraze® are being divested by Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) to Almirall together with a portfolio of other products which are principally sold by Shire in the UK, France, Germany, Italy, Spain and Ireland.

Solaraze® (diclofenac), is a topical preparation for the treatment of actinic keratoses, which are common skin lesions on areas damaged extensively by sunlight. It is marketed in the US by Doak Dermatologics, a subsidiary of Bradley Pharmaceuticals Inc. and has recently been launched in Australia by CSL Biotherapies under an agreement with Shire. SkyePharma receives a low teens royalty on relevant net sales; this is not affected by the proposed transfer from Shire to Almirall.

The transfer from Shire to Almirall is contingent on competition clearances and other customary consents.

Frank Condella, CEO of SkyePharma PLC said: "Almirall is well positioned to ensure future development and investment in Solaraze® and we expect it to get the focus it needs to continue to grow in all its key markets."

For further information please contact:
SkyePharma PLC
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer                  +44 207 491 1777
Peter Grant, Finance Director

Financial Dynamics (London enquiries)
David Yates / Deborah Scott                              +44 207 831 3113

Trout Group (US enquiries)
Christine Labaree / Seth Lewis                           +1 617 583 1308

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life- cycle extension. The Company has eleven approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.

                      This information is provided by RNS
            The company news service from the London Stock Exchange